- US Bioscience's cytoprotectant drug Ethyol (amifostine) has been cleared for marketing in Australia for its broadest range of indications yet, namely: to decrease the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents such as cyclophosphamide, mitomycin C and platinum agents; to decrease the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and for the provision of better adherence to these types of chemotherapy regimens. The drug will be marketed in Australia by a Schering-Plough affiliate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze